Effect of anagrelide on megakaryocytic cytoskeleton during platelet production. Possible genes involved

LEV PR; GLEMBOSTKY AC; BARONI PIETTO MC; CELLUCCI AS; GOETTE NP; LIRA MC; MARTA RF; YAÑUK DANILA; DE LUCA G; HELLER PG

Mar del Plata

Congreso; Reunión anual de Biociencias 2022 y LXVII Reunión anual de Sociedad Argentina de Investigación Clínica; 2022

Sociedad Argentina de Investigación Clínica

We previously reported changes in maximum platelet diameter (MPD) in patients with Phi-negative chronic myeloproliferative neoplasms treated with different drugs. Anagrelide (ANA), alfa Interferon (IFN) and ruxolitinib (Ruxo) increased MPD, while hydroxyurea (HU) decreased MPD. Evaluation of proplatelet (PP) morphology in normal megakaryocyte (MK) culture showed that ANA and IFN increased the size of tips and swellings (structures that give rise to platelets), while Ruxo and HU did not.To deepen into possible causes of these changes during ANA treatment, two approaches were carried outA) Morphological analysis of MK cytoskeleton by indirect immunofluorescence: a trend toward decreased actin polarization was observed (phalloidin-FITC), suggesting that demarcation membrane development necessary for thrombopoiesis is abnormal. Additionally, microtubular disorganization was observed (anti-alpha tubulin-FITC) (Wilcoxon test p